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PhosphorylationThe voltage dependent anion channel (VDAC) provides exchange of metabolites, anions, and cations across
the outer mitochondrial membrane. VDAC provides substrates and adenine nucleotides necessary for
electron transport and therefore plays a key role in regulating mitochondrial bioenergetics. VDAC has also
been suggested to regulate the response to cell death signaling. Emerging data show that VDAC is regulated
by protein–protein interactions as well as by post-translational modiﬁcations. This review will focus on the
regulation of VDAC and its potential role in regulating cell death in cardiac ischemia–reperfusion. This article
is part of a Special Issue entitled: VDAC structure, function, and regulation of mitochondrial metabolism.
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Mitochondria are thought to originate from gram negative bacte-
ria, and like gram negative bacteria, mitochondria have an outer and
inner membrane. The inner mitochondrial membrane has a largetructure, function, and regula-
HLBI, NIH, Room 8N202, Build-
Tel.: +1 301 496 5828.
.
.V.number of channels and transporter, whereas the voltage dependent
anion channel (VDAC) is the primary channel providing the exchange
of anions, cations and metabolites across the outer mitochondrial
membrane. VDAC is open to anions and cations at low voltage, but
at high potentials it remains open to cations but is less permeable
to anions (referred to as a closed state) [1,2]. Thus, metabolites and
anions cross the outer mitochondrial membrane in a voltage depen-
dent manner while allowing cations to pass in a voltage independent
manner [1]. Mammalian mitochondria have three VDAC isoforms,
VDAC 1, 2 and 3 [3]. The different VDAC isoforms appear to have
different localization [4] and different roles. The structure of VDAC1
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fold [5]. All beta-strands are anti-parallel except for beta1 and
beta19 that form a parallel interface.
2. VDAC regulation
VDAC is the primary channel for metabolite transfer across the
outer mitochondrial membrane. VDAC has also been shown to be a
bottleneck for Ca2+ transfer between the mitochondria and the endo-
plasmic reticulum [6]. Rapizzi et al. showed that with loss of VDAC,
there was less mitochondrial Ca2+ uptake following addition of an
IP3R stimulus [6]. VDAC has also been reported to regulate cell
death. Given the large number of roles for VDAC, it is not surprising
that there are numerous mechanisms that regulate VDAC, such as
protein–protein interactions and post-translational modiﬁcations.
2.1. Tubulin
Bernier-Valentin et al. [7], reported that tubulin, a cytoskeletal
protein and a subunit of microtubules, can attach to the outer mito-
chondrial membrane of rat liver. Carre et al. [8] demonstrated that
tubulin binds to VDAC. Tubulin, a heterodimer, has two subunits, a
and b, and both subunits bind with high afﬁnity to intact mitochon-
dria [7] through its negatively charged extended C-terminal tail
(CTT) [9]. Recently, it was shown that this anionic C-terminal tail
(CTT) is the key site for the formation of the tubulin–VDAC complex.
In an in-vitro system, Rostovtseva et al. showed that tubulin pro-
motes voltage sensitive closure of VDAC1 [10]. It has been proposed
that tubulin regulation of VDAC might explain the difference in the
Km for ADP stimulation of respiration in vivo versus that observed
in isolated mitochondria [11]. Tubulin, which would be present in
situ, would result in partial closure of VDAC and thereby increase
the apparent Km for ADP stimulation of respiration. Thus, alteration
in tubulin and the cytoskeleton are likely to alter the kinetics of
ADP and ATP exchange which could alter cell energetics and mito-
chondrial electron transport and mitochondrial membrane potential.
Consistent with a role for VDAC in regulating mitochondrial function,
Maldonado et al. [12] recently reported that modulators of VDAC
activity such as tubulin destabilizing agents and GSK-3beta inhibitors
can modulate mitochondrial membrane potential.
2.2. Hexokinase
Hexokinase I (HK) is the predominant isoform in brain, whereas
hexokinase II (HK II) is more common in heart and muscle. HKI is
typically bound to VDAC where it is suggested to promote breakdown
of glucose (glycolysis) which will supply pyruvate to the mitochon-
dria for utilization by the TCA cycle. HKII can be either cytosolic or
mitochondrial, where it binds to VDAC. HKII has been found to bind
to VDAC in cardiac and skeletal muscle [13,14] and also in HeLa
cells[15]. It is suggested that cytosolic HK enhances glycogen synthe-
sis whereas mitochondrial targeted HK promotes glycolysis [16].
Glucose-6-phosphate, the metabolite produced by HK metabolism
of glucose, is reported to lead to release of HKII from VDAC, thereby
inhibiting glycolysis. The detachment of HKII from VDAC has also
been shown to promote apoptosis. Pastorino et al. showed that phos-
phorylation of VDAC1 at Thr 51 by GSK resulted in the dissociation of
HKII from VDAC and an increase in apoptosis.
Several recent studies have shown that VDAC1 interacts with
either HKI and/or HKII [17–19], through its N-terminal region [19].
The N-terminal 29 AA residue domain for both HKI and II (HKII-
VDB; VDAC-binding domain) has high afﬁnity for VDAC [20,21],
whereas HKIII and IV lack afﬁnity for VDAC [22]. Sun et al. [23]
showed that both HKI and HKII can bind VDAC and this binding can
be facilitated by VDAC phosphorylation. Glucose and ATP both act as
a positive catalytic substrate for HK–VDAC interaction [13]. Glutamicacid 73 of VDAC is important for HK-1 binding and closure of VDAC
[24,25].
2.3. Bcl-2 family members
Several Bcl-2 family members have been reported to interact with
VDAC. VDAC2 has been shown to bind BAK and keep BAK in an inac-
tive conformation [26]. Bcl-XL has also been reported to bind to VDAC
and this interaction is suggested to reduce cell death, but there is dis-
agreement as to whether Bcl-XL binding promotes the open or closed
state of VDAC. Shimizu et al. [27], created liposomes containing VDAC
and showed that Bcl-2 family proteins regulate the release of cyto-
chrome c from the mitochondrial outer membrane. Pro-apoptotic
Bcl-2 family protein, Bax and Bak were reported to facilitate VDAC
opening, whereas the anti-apoptotic protein, Bcl-XL, closed VDAC
[27]. This same group reported that the BH4 domain of antiapoptotic
Bcl-2 family proteins, Bcl-2 and Bcl-XL, physically interacts with VDAC
and inhibits VDAC activity (VDAC closure) [28]. In contrast other
studies have suggested that Bcl-XL maintains VDAC in an open state
which facilitates metabolic exchange between cytosol and mitochon-
dria and by maintaining mitochondrial function opposes apoptosis
[29,30]. Consistent with a pro-apoptotic role for VDAC closure, in an
in-vitro study using puriﬁed VDAC from rat liver mitochondria, the
proapoptotic Bcl-2 family member Bid was shown to induce VDAC
closure [31]. Thus, there seems to be agreement that Bcl-2 family
members can bind to VDAC, but the functional effect of this interac-
tion is debated.
2.4. Post-translational modiﬁcations
Post-translational modiﬁcations have also been reported to occur
on VDAC. A number of studies have reported phosphorylation of
VDAC [15,32–36]. Deng et al. [34] performed a large scale proteomic
analysis of mitochondrial phosphoproteins and identiﬁed phosphory-
lation of Ser 117 of VDAC1. Distler et al. showed that VDAC1 was
phosphorylated on Ser 12 and Ser 136 [36]. Ser 12 is a consensus
PKC site, whereas Ser 136 is a site recognized by CAMKII/GSK. Both
GSK-3β [15,33] and PKCε [32] have been reported to phosphorylate
VDAC. PKCε has been found to interact with VDAC and inhibit the mi-
tochondrial permeability transition pore (mPTP) in cardiac mitochon-
dria [32]. VDAC1 was shown to form a VDAC–PKCε complex in a
phosphorylation dependent manner [32]. Baines et al. showed that
PKCε is translocation to the mitochondria resulting in the phosphory-
lation of VDAC1. GSK has been reported to lead to phosphorylation of
VDAC in both HeLa cells [15], and in heart [33] and both studies ﬁnd
that inhibition of GSK phosphorylation of VDAC reduces cell death.
Pastorino et al. [15] ﬁnd that inhibition of GSK reduces VDAC phos-
phorylation which results in dissociation of HKII and enhanced cell
death. Das et al. ﬁnd in rat heart that inhibition of GSK using catalytic
inhibitors, like SB 216763 or SB 415286, results in dephosphorylation
of VDAC2, along with reduced entry of ATP into the mitochondria
under de-energized conditions. This inhibition of ATP entry into the
mitochondria during anoxia would preserve the glycolytically gener-
ated ATP which would otherwise be consumed by reverse mode of
the F1 F0-ATPase [33]. Schwertz et al. (2007), also reported that p38
MAPK can phosphorylate VDAC [35].
VDAC can undergo many other post-translational modiﬁcations.
Jones and coworkers have reported that during preconditioning,
VDAC undergoes an O-glc NAcmodiﬁcation and that this modiﬁcation
correlates with cardioprotection [37]. VDAC1, VDAC2, and VDAC3 all
undergo SNO modiﬁcations [38,39]. SNO is a reversible protein mod-
iﬁcation that has the ability to alter the activity of the targeted pro-
tein. Using SNO-RAC proteomic analysis, Kohr et al. has found that
VDAC1 is S-nitrosylated on Cys 140 and 245, VDAC2 can be S-
nitrosylated on Cys 48 and 211, and VDAC3 is phosphorylated on
Cys 65 and 229 [38,39]. The functional effects of S-nitrosylation of
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VDAC was inhibited by addition of an NO donor. Interestingly, Keinan
et al. [41] have reported that apoptosis is associated with oligomeri-
zation of VDAC. S-nitrosylation has been shown to reduce oxidation
of proteins. It will be interesting to determine if S-nitrosylation of
VDAC reduces oligomerization of VDAC. Using top-down Fourier
transform mass spectrometry, Ryan et al. [42] have found that the
VDAC inhibitor Ro 68-3400 modiﬁes VDAC at Cys-232. VDAC can
also be acetylated but the consequence of this modiﬁcation needs to
be determined.
3. VDAC and cell death
3.1. VDAC as a component of mPTP
VDAC and ANT interact at contact sites between the inner and
outer membranes, and it had been suggested that mPTP might be
formed by such a complex between VDAC and ANT. However genetic
depletion studies suggested that neither ANT nor VDAC was required
for mPTP activity [43]. It would be expected that loss of VDAC would
inhibit cell death if VDAC were an obligatory component of the mPTP,
but Baines et al. showed no inhibition of cell death with loss of either
VDAC 1, 2 or 3 [43]. In agreement with other studies [26,44], Baines et
al. found that VDAC-2 null MEFS exhibited enhanced cell death.
3.2. VDAC2 and BAK
Cheng et al. [26] reported that VDAC2 binds BAK and prevents it
from activating apoptosis. However a recent study [45] shows that
VDAC2 is needed for t-BID induced apoptosis. Roy et al. [45] showed
that VDAC2 is required for truncated BID-induced mitochondrial apo-
ptosis by recruiting BAK to the mitochondria. De Stefani et al. [44]
have recently reported that loss of VDAC2 enhances apoptosis, but
that knock-down of VDAC1 reduces apoptosis.
3.3. VDAC1 and IP3R
In contrast to Baines et al. [43], De Stefani et al. [44] reported a
reduction in H2O2 mediated apoptosis in HeLa cells in which VDAC1
was reduced with siRNA, suggesting that VDAC1 promotes cell
death. Baines showed that VDAC 1/3 double null MEFs were not
protected from H2O2 or ionomycin induced death, but at some
doses showed increased death. In support of a detrimental role for
VDAC1, Abu-Hamad found an increase in apoptosis when VDAC1
was overexpressed [46]. However, Cheng et al. also found no differ-
ence in cell death in VDAC1-null MEFs treated with staurosporin
[26]. A mechanism by which VDAC1 might promote death was
provided by De Stefani et al. who report that VDAC1 forms a complex
with the IP3R which results in the transfer of apoptotic Ca signals to
the mitochondria. They ﬁnd that VDAC1 immunoprecipitates with
IP3R and it is suggested that this interaction facilitates low-amplitude
Ca transfer to the mitochondria which enhances apoptosis [44].
Grp75 is reported to be involved in linking VDAC with IP3R. Thus,
VDAC2 is involved in binding a number of Bcl-2 family members
and most reports suggest that loss of VDAC2 enhances cell death.
There are somewhat conﬂicting data regarding whether the loss of
VDAC1 is protective. Additional studies are needed to determine the
different binding partners and post-translational modiﬁcations of
different isoforms of VDAC and whether these modiﬁcations alter
cell death signaling.
3.4. VDAC2 and erastin
Erastin has been shown to bind to VDAC2 and increase cell death
in tumors with RAS activating mutations [47]. Erastin mediated cell
killing has been shown to be dependent on ERK1/2 phosphorylation;thus erastin is reported to selectively kill tumor cells that have onco-
genic activation of RAS. Erastin decreased the metabolite permeability
of VDAC as shown by a decreased NADH ﬂux through VDAC [47].
Erastin mediated death in cells with oncogenic RAS was block with
antioxidants such as α-tocopherol and BHT, suggesting that it acts
by increasing ROS or that it involves a redox sensitive modiﬁcation.
Erastin was also shown to bind VDAC2 and the ability of erastin to in-
crease cell death was lost in cell lacking VDAC2. It is interesting that
the erastin-mediated increase in cell killing is enhanced in cells
with activated RAS–MEK–ERK1/2 signaling. This might suggest that
the phosphorylation state of VDAC or some other component of the
signaling pathway is important in the erastin stimulation of death. It
will also be of interest to determine if erastin binding to VDAC2
releases BAK and whether this plays a role in the erastin mediated
killing.
3.5. Does VDAC opening/closing regulate cell death
As discussed, anti-apototic Bcl-2 family members have been
reported to interact with VDAC and modulate cell death. Most groups
ﬁnd Bcl-xl/Bcl-2 association with VDAC to reduce apoptosis, but they
differ as to whether this is mediated by an opening or closing of
VDAC.
Studies report that binding of Bcl-2 or Bcl-XL to VDAC maintains
VDAC in an open state allowing metabolite entry that serves to main-
tain mitochondrial membrane potential which opposes mPTP open-
ing [29]. Consistent with these studies Bcl-XL has been shown to
promote VDAC1 opening in a lipid bilayer [30]. There are also reports
that Bcl-XL can attenuate VDAC opening which has also been
suggested to oppose mPTP [27]. The reasons for this discrepancy are
unclear but there are several issues that should be considered.
VDAC can undergo a number of post-translational modiﬁcations and
can interact with a number of proteins. It is possible that the effect
of any one of these “modiﬁcations/interactions” could be altered
depending on what other modiﬁcations or protein interactions are
present. For example HKII binding might lead to VDAC opening in
the absence of a key post translational modiﬁcation, but could close
VDAC in the presence of these post translational modiﬁcations. A
number of elegant studies have directly examined VDAC gating in
lipid bilayers [10,31]. These studies provide very direct measure-
ments of VDAC activity, but one needs to be cautious that puriﬁed
VDAC in a bilayer might respond differently than in situ VDAC
which can be modulated by protein interactions and post translational
modiﬁcations.
Consistent with a role for VDAC closure in cell death, Tikunov et al.
[48] found that closure of VDAC with G3139, an 18-mer phosphor-
othionate, enhanced oxidative stress and led to opening of mPTP.
Tan et al. [49] showed that G3139 blocks rather than closes the
VDAC pore, resulting in decreased permeability to anions and cations
both, rather than the selective loss of anion ﬂux with VDAC closure.
Based on the kinetics they concluded that G3139 partially enters the
pore and forms an unstable bond. G3139 is a phosphorothioate
oligonucleotide, with a sulfur atom replacing a nonbridging oxygen.
Because the phosphodiester congener of G3139 does not block
VDAC it suggests a role for the sulfur atom. Tikunov et al. [48] found
that G3139 blocked superoxide anion transport from the intermem-
brane space to the cytosol, which they proposed enhanced mPTP
opening.
HK binding to VDAC attenuates apoptotic cell death [50].
Majewski et al. [20] suggest that HK binding promotes the open
conformation of VDAC. Azoulay-Zohar et al. [51] studied puriﬁed
VDAC in a bilayer and reported the HKII binding to VDAC promoted
VDAC closure. Additional studies will be required to resolve this issue.
If increased VDAC opening or closing can induce cell death, then
why does loss of VDAC have so little effect on cell death? It is likely
that if the cell is lacking all three VDAC isoforms then unless there
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altered metabolite, anion and cation exchange across the outer mito-
chondrial membrane. This loss of exchange across the outer mito-
chondria membrane would be expected to have large effects on
cellular energetics, through loss of oxidative phosphorylation, and
compensatory changes are likely. These changes could inﬂuence the
response to cell death. For example if VDAC closure reduces cell
death because it reduces ATP andmetabolite entry into the mitochon-
dria, allowing mitochondrial membrane potential to dissipate, and if
there were some compensatory protein that took over this function
with loss of VDAC (which would likely be necessary for viability of
the cell) then loss of VDAC would not alter cell death because of the
compensatory changes.
4. Does opening or closing VDAC promote cell death in cardiac
ischemia/reperfusion?
Cardiac ischemia is deﬁned as the lack of blood ﬂow to the heart,
which deprives the heart of oxygen and metabolic substrates. As
reviewed in detail elsewhere [52], if ischemia is prolonged the heart
undergoes irreversible injury. In heart, most of the ATP is generated
by electron transport and oxidative phoshorylation in the mitochon-
dria. During ischemia, with the lack of oxygen, electron transport is
inhibited and the mitochondrial membrane potential becomes depo-
larized causing oxidative generation of ATP to stop. ATP and other
high energy phosphate levels decline and anaerobic glycolysis is stim-
ulated, leading to cellular acidosis which leads to a rise in intracellular
Na via plasma membrane Na–H exchange. Na also enters the cell via
non-inactivating Na channels [52]. The resultant rise in Na leads to
an increase in cytosolic Ca via Na–Ca exchange. On reperfusion extra-
cellular pH returns to normal and this stimulate additional Na–H
which leads to further entry of Na and Ca into the cell. Oxygen is
also restored with reperfusion leading to re-energization of the mito-
chondrial membrane potential which is the driving force for Ca
uptake into the mitochondria. Elevated mitochondrial Ca can activate
the mPTP. The return of oxygen and the reenergization of the mito-
chondrial membrane potential also lead to a burst of reactive oxygen
species (ROS) which also activates mPTP.
There are a number of cardioprotective drugs and protocols that
have been shown to reduce ischemia–reperfusion injury. Brief inter-
mittent periods of ischemia and reperfusion, referred to as ischemic pre-
conditioning (IPC), have been shown to reduce ischemia–reperfusion
injury following a sustained period of ischemia. As reviewed elsewhere
IPC treatment reduces ischemic acidosis and the rise in Na and Ca that
occur during the sustained period ischemia [53]. Although IPC and
many other cardioprotective drugs reduce ischemic acidosis themecha-
nism responsible is not clear.
It might be useful to consider the functional consequence of VDAC
opening and closing in the setting of ischemia and reperfusion, which
would be different than in a more glycolytic cell in which many of the
studies examining the effect of VDAC opening/closing on cell death
have been done. There are several pieces of data consistent with a
protective role for reducing ATP entry into the mitochondria. Murry
et al. showed in their initial report on ischemia preconditioning that
IPC slowed the rate of decline in ATP [54]. Although there could be
other mechanisms involved, reduced ATP entry via VDAC would
account for this observation. Slowing the rate of ATP entry into the
mitochondria during ischemia and its subsequent consumption by
the F1F0-ATPase would allow better preservation of cell ATP [53].
The reduction in ATP breakdown would also reduce glycolysis and
generation of lactate (which was also shown to occur with IPC)
which would reduce ischemic acidosis and thereby reduce Na–H ex-
change, which otherwise would lead to an increase in intracellular
Na which in turn results in reverse mode NCX that leads to an in-
crease in Ca [52]. The ATP that is consumed by reverse mode of the
F1F0-ATPase is used to generate a mitochondria membrane potential.Although a higher membrane potential will oppose mPTP opening, a
higher membrane potential is also associated with increased genera-
tion of ROS. In addition the membrane potential is the driving force
for Ca entry into the matrix, and this matrix Ca can activate mPTP
[53]. Consistent with this concept, there are data showing a more
rapid decline in mitochondrial membrane potential during IPC [55].
Also consistent with this concept reducing mitochondrial membrane
potential prior to ischemia, for example by over expression of uncou-
pling proteins or addition of uncoupler has been shown to be
cardioprotective.
Data from Bcl-2 overexpressing heart also support a role for re-
duced ATP consumption in cardioprotection. We [56] and others
[57,58], have found that overexpression of Bcl-2 reduced ischemia–
reperfusion injury. Hearts from mice with cardiac speciﬁc overex-
pression of Bcl-2 showed improved post-ischemic recovery of left
ventricular developed pressure, reduced infarct size, and improved
post-ischemic recovery of phosphocreatine; we have also found that
when Bcl-2 is overexpressed, hearts have a slower ATP hydrolysis
rate during ischemia and reduced ischemic acidiﬁcation [56]. The
cardioprotection can be explained by the slower rate of ATP break-
down. Imahashi et al. also found VDAC association with Bcl-2 in
these hearts and that this association increased with ischemia. They
further found that binding of Bcl-2 to VDAC in isolated mitochondria
reduced ATP consumption by reverse mode of the F1 F0-ATPase under
de-energized conditions. It should be noted that these data would be
consistent with Bcl-2 inhibition of ATP entry into the mitochondria
(either by VDAC or ANT) or by a more direct inhibition of the F1-
F0-ATPase.
A study examining the protective effect of GSK inhibition provided
additional evidence for a role for VDAC. GSK is active under normal
resting conditions when it is not phosphorylated, and phosphoryla-
tion at serine 9 leads to its inactivation. Studies have shown that
GSK plays a role in ischemic preconditioning [59] and cardioprotec-
tion [60], and also targets the mPTP in cardiomyocytes [61,62]. The
mechanism by which GSK delays mPTP opening is unclear. Nishihara
et al. [62] reported that inactive GSK-3β interacts with ANT at the
inner mitochondrial membrane, which interferes with the binding
between ANT and cyclophilin D, theoretically suppressing the open-
ing of mPTP. Das et al. [33] showed that GSK-3β inhibitors preserve
ATP during ischemia by reducing adenine nucleotide transport by
VDAC [33], as summarized in Fig. 1. A role for VDAC, as opposed to
ANT was determined by measuring the conversion of ADP to AMP
by adenylate kinase located in the intermembrane space. This assay
requires adenine nucleotide transport across the outer but not the
inner mitochondrial membrane. GSK inhibitors also altered AMP pro-
duction consistent with a reduction in ADP entry via VDAC.
HKII has been shown to translocate to mitochondria with IPC [63].
Smeele et al. [64] reported that perfusing a heart with a TAT-HK pep-
tide that disrupts HKII association with the mitochondria increases
ischemia–reperfusion injury and blocks IPC mediated protection.
Although HK has been shown to bind to VDAC, it is not clear that
VDAC is the target for HKII binding in these studies. The TAT-HK pep-
tide that was used by Smeele et al. has been shown to displace HKII
from mitochondria and trigger apoptosis in cells lacking VDAC1 and
3 [65]. Thus although HKII displacement from mitochondria appears
to block IPC, it is not clear that this effect is mediated by VDAC.
5. Summary and future directions
Although VDAC does not appear to be a required component of
mPTP, there are data suggesting that VDAC can regulate cell death.
VDAC2 has been shown in many studies to attenuate cell death, in
part by binding and inactivating BAK. Other Bcl-2 family members
bind to VDAC and the effect of this binding on VDAC and/or mito-
chondrial function is still debated. Different VDAC isoforms undergo
a number of different post translational modiﬁcations and the precise
Fig. 1. Proposed VDAC involvement to protect the heart by regulating adenine nucleotide transport, either by post-translational modiﬁcations or by interaction with other proteins.
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portant area for future study. There are multiple VDAC isoforms and
their different roles and functions are just beginning to be under-
stood. Clearly VDAC is important for communication between the
mitochondria and the rest of the cell and understanding how it is
regulated will be an important area for future study.References
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